Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q3 2025
Maravai Lifesciences Holdings (MRVI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Maravai Lifesciences Holdings (MRVI) reported revenue of $41.6M for the third quarter 2025 (Q3 2025), -40% from a year earlier and -12% from the quarter before. Operating margin was -98.6%, net loss $45.1M (108.2% of revenue).
Maravai Lifesciences Holdings, Q3 2025: revenue $41.6M (-40% year over year), operating margin -98.6%, net loss $45.1M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.6M | -12% | -40% |
| Operating profit | −$41.0M | — | — |
| Net earnings | −$45.1M | — | — |
| Operating cash flow | −$15.2M | — | — |
What changed
Revenue was $41.6M in Q3 2025, down 40% year over year and down 12% from the previous quarter. Nucleic Acid Production was the largest line at 61% of revenue. Nucleic Acid Production lost $28.5M year over year (down 53%), 104% of the total change.
Gross margin was 13.6%, down 33.1 points from a year earlier. Operating costs exceeded revenue by $41.0M, an operating margin of -98.6%. Operating expenses fell 76% while revenue fell 40%. The quarter ended with a net loss of $45.1M, narrower than the previous quarter's $69.8M loss. Minority interests bore $19.5M of it: to shareholders the quarter was a loss of $25.6M.
Operating cash flow was −$15.2M. Non-cash charges added back $13.2M of depreciation and amortization and $9.1M of share-based compensation. Working capital and other items added $7.7M. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$18.1M.
Questions
What was Maravai Lifesciences Holdings' revenue in the third quarter 2025?
Maravai Lifesciences Holdings (MRVI) reported revenue of $41.6M for the third quarter 2025 (Q3 2025), -40% from a year earlier and -12% from the quarter before.
Was Maravai Lifesciences Holdings profitable in the third quarter 2025?
Operating loss was $41.0M (-98.6% of revenue) and net loss $45.1M.